Contrasting total IgG binding assays with a high-throughput SARS-CoV-2 neutralizing antibody test

A new, SARS-CoV-2, high-throughput, ELISA-based neutralizing antibody test will be described. The comparative accuracy of pre-existing EUA authorized SARS-CoV-2 IgG binding and functional neutralizing antibody serology tests in detecting natural infection/recovered individuals is contrasted. SARS-CoV-2 vaccine efficacy and evidence correlating neutralizing antibodies with protection will be reviewed. Finally, some new data comparing functional neutralizing versus total IgG binding antibody responses to vaccination will be presented. Learning Objectives: • Understand the principles of a new cPass surrogate virus neutralization test (cPass sVNT) and how it compares to the gold standard live cell virus neutralization tests such as the plaque- and foci-reducing neutralization tests. • Contrast the more traditional and commonly employed SARS-CoV-2 IgG binding assays with the functional cPass sVNT. • Discuss the variation in efficacy of current SARS-CoV-2 vaccines and uncertainties in vaccinated populations concerning protection. • Learn how cPass sVNT is distinguished from IgG binding assays in delineating between vaccinated individuals.